How do we build a world-leading business in allogeneic cell therapy for solid tumours from scratch?

Our client, a world-leading biopharmaceutical company, was looking to make significant investments to establish a differentiated presence in cell and gene therapy. The ambitious strategy aimed to leap-frog current technologies with allogeneic approaches.

We partnered closely with senior business leadership, functional workstreams and their partner biotechs to develop an integrated cross-functional strategic playbook, extensively mapping the technology landscape and critical path.

To create the foundation for implementation, we developed a strategic build-up plan to establish a fully-fledged business unit including R&D, manufacturing and commercial. By helping think cross-functionally and long term, we were able drive critical dialogue on corporate strategy.